SE443784B - Nya foreningar med farmakologisk verkan - Google Patents

Nya foreningar med farmakologisk verkan

Info

Publication number: SE443784B
Authority: SE; Sweden
Prior art keywords: methyl; compound; formula; cyano; imidazolyl
Prior art date: 1977-06-03

Application number

SE7806525A

Other languages

English (en)

Swedish (sv)

Other versions

SE7806525L (sv

Inventor

R R Crenshaw

G M Luke

Original Assignee

Bristol Myers Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1977-06-03

Filing date

1978-06-02

Publication date

1986-03-10

1977-11-07 Priority claimed from US05/848,959 external-priority patent/US4112234A/en

1978-06-02 Application filed by Bristol Myers Co filed Critical Bristol Myers Co

1978-12-04 Publication of SE7806525L publication Critical patent/SE7806525L/xx

1986-03-10 Publication of SE443784B publication Critical patent/SE443784B/sv

Links

230000000144 pharmacologic effect Effects 0.000 title 1
150000001875 compounds Chemical class 0.000 claims description 81
238000000034 method Methods 0.000 claims description 45
239000002253 acid Substances 0.000 claims description 33
150000003839 salts Chemical class 0.000 claims description 31
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 29
231100000252 nontoxic Toxicity 0.000 claims description 20
230000003000 nontoxic effect Effects 0.000 claims description 20
238000002360 preparation method Methods 0.000 claims description 14
230000008569 process Effects 0.000 claims description 13
239000002904 solvent Substances 0.000 claims description 9
239000001257 hydrogen Substances 0.000 claims description 8
229910052739 hydrogen Inorganic materials 0.000 claims description 8
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
125000000217 alkyl group Chemical group 0.000 claims description 6
125000004432 carbon atom Chemical group C* 0.000 claims description 6
125000001424 substituent group Chemical group 0.000 claims description 6
125000000304 alkynyl group Chemical group 0.000 claims description 5
239000012458 free base Chemical group 0.000 claims description 5
125000003118 aryl group Chemical group 0.000 claims description 3
125000003107 substituted aryl group Chemical group 0.000 claims description 3
125000003710 aryl alkyl group Chemical group 0.000 claims description 2
125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 1
238000006243 chemical reaction Methods 0.000 description 39
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 32
239000000047 product Substances 0.000 description 32
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
239000000203 mixture Substances 0.000 description 21
229960001380 cimetidine Drugs 0.000 description 20
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 20
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 19
229960001340 histamine Drugs 0.000 description 16
239000000243 solution Substances 0.000 description 16
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
-1 4-methyl-5-imidazolyl Chemical group 0.000 description 13
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 13
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
239000000463 material Substances 0.000 description 12
JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical compound NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 description 12
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 10
210000002837 heart atrium Anatomy 0.000 description 10
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
230000000694 effects Effects 0.000 description 9
229910052757 nitrogen Inorganic materials 0.000 description 9
238000004458 analytical method Methods 0.000 description 8
210000004051 gastric juice Anatomy 0.000 description 8
238000010992 reflux Methods 0.000 description 8
241000282472 Canis lupus familiaris Species 0.000 description 7
241000700199 Cavia porcellus Species 0.000 description 7
241001465754 Metazoa Species 0.000 description 7
238000010926 purge Methods 0.000 description 7
230000028327 secretion Effects 0.000 description 7
239000000741 silica gel Substances 0.000 description 7
229910002027 silica gel Inorganic materials 0.000 description 7
239000007787 solid Substances 0.000 description 7
239000007858 starting material Substances 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 6
LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
241000700159 Rattus Species 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
230000008018 melting Effects 0.000 description 6
238000002844 melting Methods 0.000 description 6
238000012360 testing method Methods 0.000 description 6
229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 5
230000009858 acid secretion Effects 0.000 description 5
150000001412 amines Chemical class 0.000 description 5
IULFXBLVJIPESI-UHFFFAOYSA-N bis(methylsulfanyl)methylidenecyanamide Chemical compound CSC(SC)=NC#N IULFXBLVJIPESI-UHFFFAOYSA-N 0.000 description 5
YLBIBZCIFHPPKA-UHFFFAOYSA-N but-2-yn-1-amine Chemical compound CC#CCN YLBIBZCIFHPPKA-UHFFFAOYSA-N 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
239000003485 histamine H2 receptor antagonist Substances 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
239000000543 intermediate Substances 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
238000001953 recrystallisation Methods 0.000 description 5
ACCDPTZPTFHVIV-UHFFFAOYSA-N 1-cyano-2-prop-2-ynyl-3-(2-sulfanylethyl)guanidine Chemical compound SCCNC(NC#N)=NCC#C ACCDPTZPTFHVIV-UHFFFAOYSA-N 0.000 description 4
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
244000309464 bull Species 0.000 description 4
239000006227 byproduct Substances 0.000 description 4
230000008602 contraction Effects 0.000 description 4
239000012043 crude product Substances 0.000 description 4
238000006073 displacement reaction Methods 0.000 description 4
238000004809 thin layer chromatography Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
229940126062 Compound A Drugs 0.000 description 3
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 3
102000003710 Histamine H2 Receptors Human genes 0.000 description 3
108090000050 Histamine H2 Receptors Proteins 0.000 description 3
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
239000002585 base Substances 0.000 description 3
XSBPYGDBXQXSCU-UHFFFAOYSA-N but-3-yn-1-amine Chemical compound NCCC#C XSBPYGDBXQXSCU-UHFFFAOYSA-N 0.000 description 3
239000000460 chlorine Substances 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
238000010828 elution Methods 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
230000027119 gastric acid secretion Effects 0.000 description 3
238000001802 infusion Methods 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
MWSSYOOKGBJZFI-UHFFFAOYSA-N methyl n'-but-2-ynyl-n-cyanocarbamimidothioate Chemical compound N#CN=C(SC)NCC#CC MWSSYOOKGBJZFI-UHFFFAOYSA-N 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 3
LMDDPGHBJXJGAC-UHFFFAOYSA-N pent-4-yn-1-amine Chemical compound NCCCC#C LMDDPGHBJXJGAC-UHFFFAOYSA-N 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
239000000523 sample Substances 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
RRSAAPWSPSWDIC-UHFFFAOYSA-N 1-but-3-yn-2-yl-3-cyano-2-(2-sulfanylethyl)guanidine Chemical compound C#CC(C)NC(NC#N)=NCCS RRSAAPWSPSWDIC-UHFFFAOYSA-N 0.000 description 2
LUUPYKRXMACHKV-UHFFFAOYSA-N 1-cyano-2-pent-4-ynyl-3-(2-sulfanylethyl)guanidine Chemical compound SCCNC(NC#N)=NCCCC#C LUUPYKRXMACHKV-UHFFFAOYSA-N 0.000 description 2
OGMADIBCHLQMIP-UHFFFAOYSA-N 2-aminoethanethiol;hydron;chloride Chemical compound Cl.NCCS OGMADIBCHLQMIP-UHFFFAOYSA-N 0.000 description 2
VUGCBIWQHSRQBZ-UHFFFAOYSA-N 2-methylbut-3-yn-2-amine Chemical compound CC(C)(N)C#C VUGCBIWQHSRQBZ-UHFFFAOYSA-N 0.000 description 2
239000005711 Benzoic acid Substances 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
206010065713 Gastric Fistula Diseases 0.000 description 2
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
208000008469 Peptic Ulcer Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000001746 atrial effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
235000010233 benzoic acid Nutrition 0.000 description 2
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
239000013068 control sample Substances 0.000 description 2
229940097265 cysteamine hydrochloride Drugs 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000003480 eluent Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
239000012535 impurity Substances 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
229910017604 nitric acid Inorganic materials 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
235000006408 oxalic acid Nutrition 0.000 description 2
208000011906 peptic ulcer disease Diseases 0.000 description 2
FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
238000007086 side reaction Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
229910001220 stainless steel Inorganic materials 0.000 description 2
239000010935 stainless steel Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
125000003396 thiol group Chemical group [H]S* 0.000 description 2
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
238000001665 trituration Methods 0.000 description 2
238000010626 work up procedure Methods 0.000 description 2
WTTRIOHOBKKNAU-UHFFFAOYSA-N 1-cyano-3-(2-methylbut-3-yn-2-yl)-2-(2-sulfanylethyl)guanidine Chemical compound C#CC(C)(C)NC(NC#N)=NCCS WTTRIOHOBKKNAU-UHFFFAOYSA-N 0.000 description 1
GAPFINWZKMCSBG-UHFFFAOYSA-N 2-(2-sulfanylethyl)guanidine Chemical compound NC(=N)NCCS GAPFINWZKMCSBG-UHFFFAOYSA-N 0.000 description 1
VYHWJPLNBXAXTA-UHFFFAOYSA-N 2-but-2-ynyl-1-cyano-3-(2-sulfanylethyl)guanidine Chemical compound CC#CCN=C(NC#N)NCCS VYHWJPLNBXAXTA-UHFFFAOYSA-N 0.000 description 1
XHMVFHACQKMBAS-UHFFFAOYSA-N 2-cyano-1-prop-2-ynyl-1-(2-sulfanylethyl)guanidine Chemical compound C(#N)NC(=N)N(CCS)CC#C XHMVFHACQKMBAS-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
APZXPRHPPCTRHN-UHFFFAOYSA-N 4-(chloromethyl)-5-methyl-1h-imidazole Chemical compound CC=1NC=NC=1CCl APZXPRHPPCTRHN-UHFFFAOYSA-N 0.000 description 1
PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
125000006519 CCH3 Chemical group 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 1
229910004279 O3SF Inorganic materials 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
241000736246 Pyrola Species 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
RIMGDBZXWSGBQN-UHFFFAOYSA-N burimamide Chemical compound CNC(=S)NCCCCC1=CN=C[N]1 RIMGDBZXWSGBQN-UHFFFAOYSA-N 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
238000011097 chromatography purification Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000002057 chronotropic effect Effects 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
UXOLDCOJRAMLTQ-UHFFFAOYSA-N ethyl 2-chloro-2-hydroxyiminoacetate Chemical compound CCOC(=O)C(Cl)=NO UXOLDCOJRAMLTQ-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000012065 filter cake Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
239000007789 gas Substances 0.000 description 1
210000004211 gastric acid Anatomy 0.000 description 1
201000005917 gastric ulcer Diseases 0.000 description 1
239000000499 gel Substances 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
230000005484 gravity Effects 0.000 description 1
238000011597 hartley guinea pig Methods 0.000 description 1
210000003128 head Anatomy 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229960004931 histamine dihydrochloride Drugs 0.000 description 1
PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
230000027125 histamine-induced gastric acid secretion Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
150000002541 isothioureas Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
238000013289 male long evans rat Methods 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
JMHVHSRODKCZGI-UHFFFAOYSA-N methyl n'-prop-2-ynylcarbamimidothioate Chemical group CSC(N)=NCC#C JMHVHSRODKCZGI-UHFFFAOYSA-N 0.000 description 1
AOQBTOKIEVBYSK-UHFFFAOYSA-N methyl n-cyano-n'-prop-2-ynylcarbamimidothioate Chemical compound N#CNC(SC)=NCC#C AOQBTOKIEVBYSK-UHFFFAOYSA-N 0.000 description 1
125000004372 methylthioethyl group Chemical group [H]C([H])([H])SC([H])([H])C([H])([H])* 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
101150009274 nhr-1 gene Proteins 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
239000000843 powder Substances 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
239000012264 purified product Substances 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000000611 regression analysis Methods 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
210000005245 right atrium Anatomy 0.000 description 1
238000007789 sealing Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000004448 titration Methods 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
210000003454 tympanic membrane Anatomy 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/43—Y being a hetero atom
- C07C323/44—X or Y being nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

SE7806525A 1977-06-03 1978-06-02 Nya foreningar med farmakologisk verkan SE443784B (sv)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US80300977A	1977-06-03	1977-06-03
US82679677A	1977-08-22	1977-08-22
US05/848,959 US4112234A (en)	1977-08-22	1977-11-07	Imidazolylmethylthioethyl alkynyl guanidines

Publications (2)

Publication Number	Publication Date
SE7806525L SE7806525L (sv)	1978-12-04
SE443784B true SE443784B (sv)	1986-03-10

Family

ID=27419995

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SE7806525A SE443784B (sv)	1977-06-03	1978-06-02	Nya foreningar med farmakologisk verkan
SE8401491A SE8401491L (sv)	1977-06-03	1984-03-16	Mellanprodukter for framstellning av h?712-receptorantagonister
SE8401492A SE8401492D0 (sv)	1977-06-03	1984-03-16	Mellanprodukter for framstellning av h?712-receptorantagonister

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
SE8401491A SE8401491L (sv)	1977-06-03	1984-03-16	Mellanprodukter for framstellning av h?712-receptorantagonister
SE8401492A SE8401492D0 (sv)	1977-06-03	1984-03-16	Mellanprodukter for framstellning av h?712-receptorantagonister

Country Status (26)

Country	Link
JP (1)	JPS543067A (de)
AR (2)	AR222797A1 (de)
CA (1)	CA1110251A (de)
CH (2)	CH641167A5 (de)
CY (3)	CY1229A (de)
DD (1)	DD140038A5 (de)
DE (1)	DE2824066A1 (de)
DK (1)	DK243178A (de)
ES (3)	ES470474A1 (de)
FI (1)	FI69069C (de)
FR (2)	FR2401143A1 (de)
GB (3)	GB1598628A (de)
GR (1)	GR73860B (de)
HK (3)	HK38184A (de)
HU (1)	HU186766B (de)
IE (1)	IE47543B1 (de)
IL (1)	IL54819A (de)
KE (1)	KE3373A (de)
LU (1)	LU79725A1 (de)
MY (3)	MY8500453A (de)
NL (1)	NL7805935A (de)
NO (3)	NO152214C (de)
NZ (1)	NZ187376A (de)
SE (3)	SE443784B (de)
SG (1)	SG8584G (de)
YU (4)	YU129778A (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS568352A (en) *	1979-07-03	1981-01-28	Shionogi & Co Ltd	Aminoalkylvenzene derivative
US4339439A (en) *	1981-01-19	1982-07-13	Bristol-Myers Company	Pharmaceutical methods and compositions
JPS6018010U (ja) *	1983-07-18	1985-02-07	日産自動車株式会社	車両用空気調和装置の温度調整機構
JPS60113211U (ja) *	1984-01-06	1985-07-31	松下電器産業株式会社	自動車用空気調和装置
ES2007948A6 (es) *	1988-07-06	1989-07-01	Vinas Lab	Procedimiento para la obtencion de derivados propargilguanidicos.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1338169A (en) *	1971-03-09	1973-11-21	Smith Kline French Lab	Ureas thioureas and guanidines
US4024271A (en) *	1971-03-09	1977-05-17	Smith Kline & French Laboratories Limited	Pharmacologically active guanidine compounds
GB1397436A (en) *	1972-09-05	1975-06-11	Smith Kline French Lab	Heterocyclic n-cyanoguinidines
GB1531221A (en) *	1974-09-02	1978-11-08	Smith Kline French Lab	Process for preparing guanidine derivatives
GB1533380A (en) *	1974-09-02	1978-11-22	Smith Kline French Lab	Process for the preparation of heterocyclic substituted thioureas and h-cyanoguanidines
GB1531231A (en) *	1974-09-02	1978-11-08	Smith Kline French Lab	Process for the production of cyanoguanidine derivatives

1978
- 1978-05-25 NZ NZ187376A patent/NZ187376A/xx unknown
- 1978-05-25 CA CA304,045A patent/CA1110251A/en not_active Expired
- 1978-05-26 GB GB23611/78A patent/GB1598628A/en not_active Expired
- 1978-05-26 GB GB18923/80A patent/GB1598630A/en not_active Expired
- 1978-05-26 CY CY1229A patent/CY1229A/en unknown
- 1978-05-26 GB GB27637/79A patent/GB1598629A/en not_active Expired
- 1978-05-26 CY CY1230A patent/CY1230A/en unknown
- 1978-05-26 CY CY1231A patent/CY1231A/en unknown
- 1978-05-29 GR GR56374A patent/GR73860B/el unknown
- 1978-05-29 LU LU79725A patent/LU79725A1/xx unknown
- 1978-05-31 DK DK243178A patent/DK243178A/da not_active Application Discontinuation
- 1978-05-31 NL NL7805935A patent/NL7805935A/xx not_active Application Discontinuation
- 1978-05-31 FI FI781737A patent/FI69069C/fi not_active IP Right Cessation
- 1978-05-31 YU YU01297/78A patent/YU129778A/xx unknown
- 1978-05-31 AR AR272401A patent/AR222797A1/es active
- 1978-05-31 IL IL54819A patent/IL54819A/xx unknown
- 1978-06-01 DE DE19782824066 patent/DE2824066A1/de not_active Withdrawn
- 1978-06-02 CH CH609278A patent/CH641167A5/de not_active IP Right Cessation
- 1978-06-02 FR FR7816601A patent/FR2401143A1/fr active Granted
- 1978-06-02 ES ES470474A patent/ES470474A1/es not_active Expired
- 1978-06-02 HU HU811135A patent/HU186766B/hu unknown
- 1978-06-02 SE SE7806525A patent/SE443784B/sv unknown
- 1978-06-02 JP JP6590078A patent/JPS543067A/ja active Granted
- 1978-06-02 NO NO781928A patent/NO152214C/no unknown
- 1978-06-02 IE IE1112/78A patent/IE47543B1/en unknown
- 1978-06-05 DD DD78205794A patent/DD140038A5/de unknown
1979
- 1979-03-01 ES ES478203A patent/ES478203A1/es not_active Expired
- 1979-03-01 ES ES478202A patent/ES478202A1/es not_active Expired
- 1979-03-05 YU YU530/79A patent/YU41620B/xx unknown
- 1979-05-16 NO NO791637A patent/NO791637L/no unknown
- 1979-10-26 AR AR278645A patent/AR222503A1/es active
- 1979-11-23 FR FR7928943A patent/FR2436138A1/fr active Granted
1982
- 1982-09-27 YU YU2155/82A patent/YU40625B/xx unknown
- 1982-09-27 YU YU2154/82A patent/YU40624B/xx unknown
1983
- 1983-09-12 NO NO833255A patent/NO151824C/no unknown
- 1983-10-07 CH CH549283A patent/CH644591A5/de not_active IP Right Cessation
1984
- 1984-01-30 SG SG85/84A patent/SG8584G/en unknown
- 1984-02-10 KE KE3373A patent/KE3373A/xx unknown
- 1984-03-16 SE SE8401491A patent/SE8401491L/xx not_active Application Discontinuation
- 1984-03-16 SE SE8401492A patent/SE8401492D0/xx not_active Application Discontinuation
- 1984-05-03 HK HK381/84A patent/HK38184A/xx unknown
- 1984-05-03 HK HK382/84A patent/HK38284A/xx unknown
- 1984-05-03 HK HK380/84A patent/HK38084A/xx unknown
1985
- 1985-12-30 MY MY453/85A patent/MY8500453A/xx unknown
- 1985-12-30 MY MY451/85A patent/MY8500451A/xx unknown
- 1985-12-30 MY MY452/85A patent/MY8500452A/xx unknown

Also Published As

Publication number	Publication date
YU215482A (en)	1983-02-28
HU186766B (en)	1985-09-30
CH641167A5 (en)	1984-02-15
MY8500451A (en)	1985-12-31
MY8500453A (en)	1985-12-31
ES470474A1 (es)	1979-09-01
CA1110251A (en)	1981-10-06
FR2436138B1 (de)	1982-12-03
NO833255L (no)	1978-12-05
SG8584G (en)	1985-02-08
CY1231A (en)	1984-06-29
SE8401491D0 (sv)	1984-03-16
IE47543B1 (en)	1984-04-18
FR2401143B1 (de)	1981-12-11
HK38084A (en)	1984-05-11
AR222503A1 (es)	1981-05-29
MY8500452A (en)	1985-12-31
HK38184A (en)	1984-05-11
ES478202A1 (es)	1979-06-01
NZ187376A (en)	1981-05-29
NO152214B (no)	1985-05-13
IL54819A0 (en)	1978-07-31
NL7805935A (nl)	1978-12-05
FI781737A7 (fi)	1978-12-04
DD140038A5 (de)	1980-02-06
YU40625B (en)	1986-02-28
IE781112L (en)	1978-12-03
YU41620B (en)	1987-12-31
YU53079A (en)	1983-09-30
CY1230A (en)	1984-06-29
NO151824B (no)	1985-03-04
YU40624B (en)	1986-02-28
NO791637L (no)	1978-12-05
GB1598629A (en)	1981-09-23
YU129778A (en)	1983-02-28
NO781928L (no)	1978-12-05
IL54819A (en)	1983-03-31
DE2824066A1 (de)	1978-12-14
FI69069B (fi)	1985-08-30
CH644591A5 (en)	1984-08-15
FR2401143A1 (fr)	1979-03-23
FR2436138A1 (fr)	1980-04-11
AR222797A1 (es)	1981-06-30
GB1598630A (en)	1981-09-23
ES478203A1 (es)	1979-06-01
GB1598628A (en)	1981-09-23
DK243178A (da)	1978-12-04
HK38284A (en)	1984-05-11
NO151824C (no)	1985-06-12
FI69069C (fi)	1985-12-10
NO152214C (no)	1985-08-28
JPS5639313B2 (de)	1981-09-11
SE8401492L (sv)	1984-03-16
GR73860B (de)	1984-05-08
SE8401492D0 (sv)	1984-03-16
SE7806525L (sv)	1978-12-04
SE8401491L (sv)	1984-03-16
CY1229A (en)	1984-06-29
JPS543067A (en)	1979-01-11
LU79725A1 (fr)	1979-02-02
YU215582A (en)	1983-02-28
KE3373A (en)	1984-03-23

Publication	Publication Date	Title
Petersen et al.	1978	Synthesis and hypotensive activity of N-alkyl-N''-cyano-N'-pyridylguanidines
IE53274B1 (en)	1988-09-28	Chemical compounds derived from cyclobutene
US4112234A (en)	1978-09-05	Imidazolylmethylthioethyl alkynyl guanidines
JPH03169860A (ja)	1991-07-23	置換ｎ―ベンジルピペリジンアミド
HU187478B (en)	1986-01-28	Process for preparing new imidazolyl-phenyl-amidines and pharmaceutical compositions containing thereof
US20040254221A1 (en)	2004-12-16	Novel Nitrogenous Compound and use thereof
SU1241986A3 (ru)	1986-06-30	Способ получени производных бензамида,их гидрохлоридов или оптических изомеров
CN1022246C (zh)	1993-09-29	1-酰基-3-(4-(2-嘧啶基)-1-哌嗪基)丙烷的制备方法
CA1240325A (en)	1988-08-09	4-amino-2-piperidinoquinazolines
McKay et al.	1956	Amino Acids. II. Synthesis of Cyclic Guanidino Acids1
SE443784B (sv)	1986-03-10	Nya foreningar med farmakologisk verkan
US3030371A (en)	1962-04-17	Process for the preparation of d-and l-aryl-(2-pyridyl)-amino alkanes
EP0220653B1 (de)	1991-11-06	3-Aminocarbonyl-1,4-dihydropyridin-5-carboxylsäurederivate, Verfahren zu ihrer Herstellung, ihre Verwendung und diese enthaltende pharmazeutische Zusammensetzungen
US4157340A (en)	1979-06-05	N,N'-[Bis(N-cyanoguanyl)]cystamine derivatives
FI62095C (fi)	1982-11-10	Foerfarande foer framstaellning av nya 1- och d1-6-/m-(isoxazol-3-karboxiamido)fenyl)-2,3,5,6-tetrahydroimidazo(2,1-b)tiazolderivat vilka anvaends som maskmedel
CH632999A5 (fr)	1982-11-15	(2-thio)urees 1,3-disubstituees.
US4200760A (en)	1980-04-29	Imidazolylalkylthioalkylamino-ethylene derivatives
KR860000516B1 (ko)	1986-05-02	페네틸피페리딘 화합물의 제조방법
EP0180500A1 (de)	1986-05-07	Thieno- und Furo[2,3-c]pyrrolderivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
JPH0723349B2 (ja)	1995-03-15	３，５−ジ−タ−シヤリ−ブチル−４−ヒドロキシケイ皮酸アミド誘導体
KR810000632B1 (ko)	1981-06-10	히스타민 h₂수용기 길항제 또는 비독성인 그의 약조제 가능한 산 첨가염의 제조방법
CA1247623A (en)	1988-12-28	Derivatives of 2-(2-thienyl)-imidazo-¬4,5-b\|- pyridines and their pharmaceutically acceptable salts and a process for the preparation thereof
US3498978A (en)	1970-03-03	3-pipecoline derivatives
USRE31588E (en)	1984-05-22	Imidazolylmethylthioethyl alkynyl guanidines
US2503652A (en)	1950-04-11	Nu-phenethyl-beta-alanine derivatives